Pope Leo XIV marks 56th anniversary of moon landing with observatory visit, call to Buzz Aldrin
ROME: Pope Leo XIV marked the 56th anniversary of man's arrival on the moon Sunday with a visit to the Vatican astronomical observatory in Castel Gandolfo and a call to astronaut Buzz Aldrin.
After praying the Sunday Angelus at his summer retreat in Castel Gandolfo, Leo headed to the astronomical observatory located in the Pontifical Villas, where he took a close look at the telescopes that have supported celestial exploration from a faith-based perspective for decades.
The pontiff was accompanied by astronomers and students participating in the traditional summer school organised by the observatory.
This was Pope Leo's first visit to the observatory, founded in 1891 by Leo XIII. The first vision of it, however, can be traced back to the establishment by Pope Gregory XIII of a commission aimed at studying the scientific data and implications of the calendar reform that took place in 1582.
The Vatican Observatory has generated top-notch research from its scientist-clerics, drawing academics to its meteorite collection, which includes bits of Mars and is considered among the world's best.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
American Investor Warren Buffett Recommends: 5 Books For Turning Your Life Around
Blinkist: Warren Buffett's Reading List
Undo
Later Sunday, the pope called astronaut Buzz Aldrin, who shared with Neil Armstrong and Michael Collins the historic 1969 moonwalk.
"This evening, 56 years after the Apollo 11 moon landing, I spoke with the astronaut Buzz Aldrin," Pope Leo wrote on his X account. "Together we shared the memory of a historic feat, a testimony to human ingenuity, and we reflected on the mystery and greatness of Creation."
Pope Leo then blessed the astronaut, his family and his collaborators.
There are a few precedents of papal calls to "space."
In 2011, Pope Benedict XVI rang the space station and asked about the future of the planet and the environmental risks it faced.
Before Benedict, Pope Paul VI sent a radio message to astronauts Armstrong, Aldrin and Collins after their moonwalk, calling them "conquerors of the Moon."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
On a weight loss journey? Eating THIS nut can help drop the kilos, naturally
Research indicates that incorporating almonds into your diet may aid in weight management. A study revealed that consuming almonds as snacks can lead to a reduction in daily kilojoule intake, primarily by curbing the consumption of junk food. Almond consumption influences appetite-regulating hormones, potentially contributing to decreased food intake and promoting overall health. Weight loss is a tough nut to crack, but having a handful of a certain nut can really help you with it. Yes, that's right. Obesity rates are on the rise across the world. Being obese or overweight is more than a cosmetic concern; it can raise the risk of many diseases, including diabetes, fatty liver, and even certain cancers. Weight management is crucial for overall wellness. So how exactly do you manage weight or lose those extra pounds? Add a few almonds to your diet. Yes, that's right. A 2022 study led by researchers at the University of South Australia found that almonds may help you cut calories. The findings are published in the European Journal of Nutrition . Almonds Almonds are edible seeds of Prunus dulcis, aka the almond tree. Native to the Middle East, almonds are enjoyed by people across the world. These nuts are high in antioxidants, vitamin E, protein, and fiber. A 1-ounce or 28 g, serving of almonds contains : Fiber: 3.5 g Protein: 6 g Fat: 14 g (9 of which are monounsaturated) Vitamin E: 48% of the daily value (DV) Manganese: 27% of the DV Magnesium: 18% of the DV Copper, vitamin B2 (riboflavin), and phosphorus Can almonds help with weight loss A handful of almonds could keep extra kilos at bay, according to new research. The researchers found that eating almonds can affect appetite. Having 30-50 grams of almonds as snacks could help people cut back on the number of kilojoules they consume each day. They found that people who consumed almonds lowered their energy intake by 300 kilojoules (most of which came from junk food) at the subsequent meal, when compared to an energy-equivalent carbohydrate snack. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 15 most beautiful women in the world Undo 'Rates of overweight and obesity are a major public health concern, and modulating appetite through better hormonal response may be key to promoting weight management,' Dr. Sharayah Carter from UniSA's Alliance for Research in Exercise, Nutrition and Activity (ARENA) said, in a statement. Sharing further about the research, Carter added, 'Our research examined the hormones that regulate appetite, and how nuts – specifically almonds - might contribute to appetite control. We found that people who ate almonds experienced changes in their appetite-regulating hormones, and that these may have contributed to reduced food intake (by 300kJ).' Obesity and almonds Obesity is on the rise across the globe. In 2022, about nine billion adults were overweight, with 650 million of these being obese. According to the data by the World Health Organization ( WHO ), 1 in 8 people in the world were living with obesity in 2022. To understand the weight loss effects of almonds, the researchers studied some people, and found that the ones who ate almonds had 47% lower C-peptide responses (which can improve insulin sensitivity and reduce the risk of developing diabetes and cardiovascular disease); and higher levels of glucose-dependent insulinotropic polypeptide (18 per cent higher), glucagon (39 per cent higher), and pancreatic polypeptide responses (44 per cent higher). The glucagon gives a sense of satiety, and the pancreatic polypeptide slows digestion. This reduces the food intake, leading to weight loss. 'Almonds are high in protein, fibre, and unsaturated fatty acids, which may contribute to their satiating properties and help explain why fewer kilojoules were consumed,' Dr. Carter said. Orange for weight loss: How eating oranges everyday can help you lose belly fat The researcher also pointed out that, through the study, they found that almonds produce small changes to people's energy intake. 'Even small, positive lifestyle changes can have an impact over a longer period. When we're making small, sustainable changes, we're more likely to be improving our overall health in the long run. Almonds are a fantastic healthy snack to incorporate into the daily diet. We are now excited to look at how almonds might affect appetite during a weight loss diet and how they might assist with weight management in the long term,' Dr Carter added.
Time of India
an hour ago
- Time of India
Not just Homo Sapiens: There were 20+ human species that walked the Earth with the modern man; Where are they now?
Once, Earth was home to diverse human species, not just Homo sapiens. Fossil evidence reveals at least 21 early human species, including Neanderthals and Denisovans, coexisted and even interbred with our ancestors. While the reasons for their extinction remain a mystery, factors like climate change, competition, and interbreeding likely played roles. Modern humans are often seen as the pinnacle of evolution and the only ones to have grown and developed over centuries. But in evolutionary terms, not long ago, we shared the planet with a number of other human species. These ancient relatives were not just distant ancestors but our contemporaries, walking the Earth at the same time with our ancestors, even in the same places. They lived, adapted, created tools, even interacted and had children with us. The picture of human evolution is not a straight line from primitive to modern but rather a tangled tree with many branches, where some of these branches ended in extinction and others merged. But who are the other types of human species that walked along the ancestors of the Homo Sapiens, and why couldn't they survive till today? A crowded family tree For most of human history, Homo sapiens weren't alone. Fossil evidence shows that at least 21 species of early humans once roamed the Earth. These included well-known relatives like Neanderthals, as well as Homo Naledi and Homo Luzonensis, as suggested by recent fossil discoveries. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like This Could Be the Best Time to Trade Gold in 5 Years IC Markets Learn More Undo Among these, some species lasted millions of years, while others were short-lived experiments in survival. The modern Homo Sapiens didn't just follow other human species; they overlapped with them. Homo sapiens lived alongside Neanderthals and Denisovans, sometimes for thousands of years. In some regions, they shared regional tools and even genes. Interbreeding between Homo sapiens and these relatives left traces in the DNA, especially in populations today outside Africa. These weren't short-lived events; they were complex interactions between intelligent, adaptable beings trying to survive a shifting world. In fact, any of these species wasn't alone; they were part of a larger and connected human world. The mystery of the missing species Despite advances in archaeology and genetics, many early human species remain a mystery. Some are known only from a few bones or teeth, like the Denisovans, for example, whose full skeleton has not been found till date. Instead, their story is put together from fragments and DNA. Scientists continue to debate how many species truly existed, since definitions of "species" can vary. Did they look different enough? Could they have kids together? These uncertainties mean the real number of human species might be far higher than 21. Why could only one species make it to today? The reasons aren't fully clear. It could be that they were more adaptable, better at cooperating, or just luckier. Climate change, competition for resources, and even disease may have wiped out other human species. Some were already disappearing when we arrived. Others may have blended into our gene pool through interbreeding. But there is one certainty that survival wasn't guaranteed; Homo Sapiens' today came at the cost of other lost human lineages.
Time of India
an hour ago
- Time of India
Glioblastoma breakthrough: 40-year-old dad is brain cancer-free after groundbreaking immunotherapy trial
In a surprising and hopeful turn of events, a 40-year-old father is living his best life in his second innings, after he was diagnosed with terminal glioblastoma in 2023. In fact, three years later, he is not only healthy and thriving, but his brain cancer has completely 'vanished'! How? Read on to know more. What happened? In October 2022, 40-year-old Ben Trotman was diagnosed with terminal glioblastoma, the most common and deadliest form of brain cancer that typically carries a grim prognosis with a median survival of just 12–18 months. Yet, over two years after receiving a single dose of ipilimumab before standard care, Trotman reportedly remains cancer-free and healthy as ever. Under the care of consultant oncologist Dr. Paul Mulholland at UCLH (University College London Hospital), Trotman became part of an NHS-funded trial that administers ipilimumab, a checkpoint inhibitor designed to boost the immune system, before traditional surgery, radiotherapy, and chemotherapy. Two years later, his scans show no signs of recurrence, an unprecedented outcome in glioblastoma treatment. The medical marvel The new clinical trial for the most deadly type of brain cancer, glioblastoma, which helped Ben with another shot at life, is looking for patients to join after an incredible success story. Organized by the NHS, this study aims to enroll 16 people over 18 months and is dedicated to Baroness Margaret McDonagh, who lost her battle with the disease. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Villas For Sale in Dubai Might Surprise You Dubai villas | search ads Get Deals Undo Patients diagnosed with glioblastoma will receive an immunotherapy drug called ipilimumab before starting standard treatments, making the most of their immune systems when they are at their strongest. The trial is being led by experts at University College London Hospital's National Hospital for Neurology and Neurosurgery. It follows a previous study with the same drug, which had to close because not enough patients joined. The trial honors the late Baroness Margaret McDonagh's memory and, like Trotman, participants receive ipilimumab to prime their immune defenses, with hopes of replicating his reassuring response. Ipilimumab: The key behind the breakthrough Ipilimumab is a monoclonal antibody that blocks CTLA-4, an immune checkpoint. In cancers like melanoma, it enhances T-cell activity, enabling the body to attack tumors. When used before standard glioblastoma therapy, it primes the immune system to better target cancer cells. In Trotman's case, it appears to have either eradicated or dramatically controlled his tumor, an outcome never before reported in this context. This 'window-of-opportunity' pre-treatment approach is groundbreaking. By delivering immunotherapy before surgery, it maximizes immune activation and potentially aids post-operative cancer control, a novel strategy in glioblastoma care. What is glioblastoma? Glioblastoma, previously known as glioblastoma multiforme or GBM, is the most common and aggressive type of primary brain cancer in adults. Glioblastoma originates from astrocytes, a type of glial cell that supports nerve cells in the brain and spinal cord. Glioblastoma is classified as a Grade IV tumor, meaning it's highly aggressive, grows rapidly, and infiltrates surrounding brain tissue. The exact cause of most glioblastomas is unknown. However, it is understood that the disease develops when brain cells undergo DNA mutations that cause them to grow and multiply uncontrollably. The prognosis for glioblastoma is generally poor, with a median survival of about 12-18 months after diagnosis. The five-year survival rate is around 5%, meaning about 5% of patients are still alive five years after their diagnosis. Glioblastoma almost always recurs despite maximal treatment. Hence, Trotman's cancer-free scans more than two years post-treatment represent a hopeful breakthrough. It suggests that bolstering immune readiness before conventional treatment might overcome glioblastoma's defenses. The success story The success story comes from Ben Trotman, who was diagnosed in October 2022 at the age of 40. Now, at 43, two years and eight months after his treatment, his scans are clear, and there are no traces of the tumor. Dr. Paul Mulholland, the consultant medical oncologist who is leading this new trial and treated Ben, as reported by The Independent, shared, 'It is very unusual to have a clear scan with glioblastoma, especially when he didn't have the follow-up surgery that had been planned to remove all of the tumor that was initially visible on scans. We hope that the immunotherapy and follow-up treatment Ben has had will hold his tumor at bay – and it has so far, which we are delighted to see. ' Ben's life has changed significantly since his diagnosis; he got married to Emily just two months after receiving the immunotherapy treatment, and in April, they welcomed their daughter, Mabel. Emily expressed the emotional toll of Ben's diagnosis, saying, 'Getting this diagnosis was the most traumatic experience. We were grappling with the fact that Ben had gone from being apparently perfectly healthy to having months to live. Had we not met Dr. Mulholland, that would have been it for us. We felt we had a lucky break in an otherwise devastating situation.' After the immunotherapy, Ben went on to have the standard treatments of radiotherapy and chemotherapy. He continues to have quarterly scans, which remain clear. Ben reflected on their journey, stating, 'We obviously don't know what the future holds, but having had the immunotherapy treatment and getting these encouraging scan results has given Emily and me a bit of hope. We are focused on rebuilding the life we thought we had lost and enjoying being parents. ' Dame Siobhain McDonagh MP led a successful fundraising campaign that gathered over £1 million to support this new trial. Her sister, Baroness McDonagh, sadly passed away from glioblastoma in 2023. Dame Siobhain shared, 'My beloved sister Margaret was appalled to discover that there had been no advances in brain cancer treatment for decades when she was diagnosed with glioblastoma. Changing this was Margaret's final campaign and one that I have continued in her memory. I am so grateful to the many people who knew and respected Margaret, who have come together and helped to raise funds and campaign for this new trial that we are calling Margaret's Trial.' Dr. Mulholland is also thankful for Margaret and Siobhain's dedication, stating, 'When I met Margaret, she said to me, 'What can I do to support you to cure this disease?'. I am incredibly grateful to her and to Siobhain, whose campaigning and fundraising in her sister's memory have led to this new clinical trial opening for patients with this most aggressive form of brain cancer that has such a poor prognosis, with most patients surviving just nine months after diagnosis. The crucial element of this trial is that patients will have their immune system boosted by the drug before they have any other treatment, when they are fit and well enough to tolerate the immunotherapy. We're taking everything we have learned from previous trials into this new study, and we are already planning follow-on trials. My aim is to find a cure for glioblastoma.' What's ahead? Led by Dr. Mulholland, the trial is expanding enrollment, aiming to confirm both safety and effectiveness. Currently, the National Brain Appeal is funding two positions to support Dr. Mulholland's vital research. The treatment will take place at the NIHR UCLH's Clinical Research Facility and the National Hospital for Neurology and Neurosurgery. Patients who are interested in participating in the new Win-Glio trial should discuss it with their consultant.
